Allosteric Bcr-Abl Tyrosine Kinase Inhibitor ABL001

Known as: ABL001

An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, ABL001…

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2018

2017

Discovery [2] ABL001 is a small molecule designed to inhibit BCR-ABL, the same protein hit by imatinib and nilotinib, which are…